During Tuesday’s trading session, shares of a global biopharmaceutical company engaged in the manufacturing of biotechnology products and research services are in focus, after the company launched a Qualified Institutions Placement (QIP) to raise up to Rs. 4,500 crores.
- Tata Motors shares slip even as US-UK trade deal brings respite to JLR; Buy, sell or hold?
- Upcoming dividend stock: Bajaj Auto, & 24 others to go ex-date next week
- Bajaj Finance shares didn’t crash 90%! Here’s what a stock split and bonus really mean
- Israel, Iran Trade Blows for Third Day With No Sign of Letup
- NEET UG Result 2025 Live Updates: NTA results declared at neet.nta.nic.in, check how to download scorecard and other key details
With a market cap of Rs. 43,077.5 crores at 10:18 a.m, the shares of Biocon Limited (NSE: BIOCON) were trading in the green at Rs. 358.8 on BSE, up by 0.4 percent, as against its previous closing price of Rs. 357.3. The stock has delivered positive returns of around 9 percent in one year, and has gained by over 5 percent in the last one month.
What’s the News
According to the latest regulatory filings, the Board of Biocon Limited has given the green light to launch a qualified institutional placement (QIP) on 16th June 2025, to eligible qualified institutional buyers, aimed at raising up to Rs. 4,500 crores. The company has set a floor price of Rs. 340.2 per equity share for the issue.
This decision comes on the back of earlier approvals—first by the company’s Board in April, and more recently by shareholders through a postal ballot conducted earlier this month. During its meeting on 16th June, the Fund Raising Committee formally approved the opening date of the issue, confirmed the floor price, and cleared the preliminary placement document dated the same day.
Additionally, the regulatory filing noted that the company has the discretion to offer a discount of up to 5 percent on the floor price. The final QIP issue price will be determined by Biocon after consulting with the book-running lead managers for the issue.
Financials & more
Biocon reported a significant growth in its revenue from operations, showing a year-on-year rise of around 13 percent from Rs. 3,917 crores in Q4 FY24 to Rs. 4,417 crores in Q4 FY25. Similarly, its net profit increased during the same period from Rs. 223 crores to Rs. 459 crores, representing an impressive growth of around 106 percent YoY.
Biocon Limited is engaged in the business of manufacturing biotechnology products and research services. It is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.
